US ENT Partners recently hosted an insightful Spotlight Webinar focused on one of the fastest-growing topics in ENT today: biologics and buy-and-bill programs.
The session featured Dr. Keith Matheny alongside Elizabeth Johnson, CEO of Medico CX, widely recognized as a leading expert in biologics operations, reimbursement strategy, and practice implementation.
Why Biologics Matter in ENT
Biologics are rapidly transforming the treatment landscape for chronic rhinosinusitis with nasal polyps and asthma-related inflammatory disease. During the webinar, Dr. Matheny highlighted the increasing adoption of biologic therapies across ENT practices nationwide and the growing need for operational strategies that make these therapies sustainable for practices.
A major focus of the discussion was Tezspire, a biologic therapy that has been used successfully for asthma treatment for several years and recently received approval for nasal polyp patients.
According to Dr. Matheny, clinical outcomes have shown Tezspire to be highly effective, with results that are comparable, and potentially superior, to other commonly used biologics in the space.
Understanding the Buy-and-Bill Opportunity
One of the most valuable parts of the webinar centered around the “buy-and-bill” model, an approach that allows practices to purchase biologic medications directly, administer them in-office, and bill payers accordingly.
Elizabeth Johnson explained how this model creates opportunities for practices to:
- Improve patient access to biologic therapies
- Gain greater control over treatment workflows
- Reduce administrative complexity
- Generate additional revenue streams through reimbursement and rebates
The discussion also covered how manufacturers structure rebate programs based on purchasing volume and how group purchasing power through US ENT Partners can create additional financial advantages for member practices.
The Medico CX BOSS Program
For practices new to biologics and buy-and-bill workflows, Medico CX introduced its BOSS Program, designed to simplify implementation and reduce operational risk.
The program helps practices manage:
- Drug purchasing and inventory
- Administration schedules
- Claims processing and reimbursement tracking
- Staff education and workflow optimization
Dr. Matheny described the program as a “no-brainer” for practices looking to enter the biologics space without overwhelming internal teams.
Growing Momentum Across US ENT Partners
The webinar concluded with encouraging updates on adoption across the US ENT Partners network. Many practices have already started implementing biologic programs and treating patients through buy-and-bill workflows.
As biologics continue to reshape ENT care, partnerships like the collaboration between US ENT Partners and Medico CX are helping practices confidently navigate the operational and financial complexities of these therapies.
Continue the Conversation
Reach out to the US ENT Partners team at membersupport@usentpartners.com to continue the conversation or get connected with the appropriate resources.